LLY Jan 2026 1260.000 call
| Previous close | 51.70 |
| Open | 52.30 |
| Bid | 0.00 |
| Ask | 0.00 |
| Strike | 1,260.00 |
| Expiry date | 2026-01-16 |
| Day's range | 51.70 - 52.35 |
| Contract range | N/A |
| Volume | |
| Open interest | N/A |
- Yahoo Finance Video
How consumer spending, election impact markets: Market Domination
On today's episode of Market Domination, hosts Julie Hyman and Josh Lipton cover how major trends like weak consumer spending and the election are impacting the markets (^DJI, ^IXIC, ^GSPC). As the S&P 500 (^GSPC) and Nasdaq (^IXIC) snap their three-day losing streak, Roundhill Investments CEO Dave Mazza joins the show to give insight into the market movement. He explains, "The mega-cap companies, the 'Magnificent Seven,' have really been the star performers and folks who are looking for a rotation, whether it's to small caps or even other cyclical sectors like industrials and financials, haven't seen it yet. So it doesn't give people really a lot of confidence, even though to your point, for all intents and purposes, they should be particularly bullish. Look at money market assets, money in money market mutual funds are at all time highs. So it's sort of this weird environment where folks are seeking out safety." The pharmaceutical industry is seeing significant movement. Shares of Moderna (MRNA) are falling after the company said its newly approved RSV vaccine was only about 50% effective after 18 months. Meanwhile, the US House Ways and Means Committee has proposed a strategy for Medicare to cover GLP-1 weight-loss drugs like Novo Nordisk's (NVO) Wegovy and Eli Lily's (LLY) Zepbound. The amendment to the Treat and Reduce Obesity Act of 2023 will be voted on in Thursday's session. In the latest edition of Good Buy or Goodbye, Tematica Research chief investment officer Chris Versace explains why Costco (COST) is a better investment than McDonald's (MCD) amid weak consumer spending. Versace sees Costco (COST) as a buying opportunity as the retail giant is "extremely well positioned," with about 54% of its product revenue coming from fresh food and sundries. On the other hand, he is bearish on McDonald's, explaining that despite rolling out value meals, the fast food giant is "no longer the cheap alternative." As the 2024 presidential election inches closer, Blue Line Futures chief market strategist Phil Streible joins the show to highlight how each administration may affect the commodity market. He states, "Energies are one of the top focuses that we're going to be watching. Under Trump, we were energy independent. We did also have a hard stance on Iran. It makes a play for lower energy prices if Trump was to come into office where we are much more dependent on OPEC, South American oil, it's very difficult for oil and gas exploration companies to get those permits to expand wells." This post was written by Melanie Riehl
- Yahoo Finance Video
Novo Nordisk, Eli Lilly still top 2 pharma stocks: Analyst
Novo Nordisk (NVO) and Eli Lilly (LLY) both made headlines recently with positive drug trial results for their respective GLP-1 weight-loss drugs, as well as their approval in China. While these names have been often cited as top picks in the pharmaceutical industry, are there hidden gems to look out for or do Eli Lilly and Novo Nordisk remain at the top of the class? Mizuho Healthcare Equity Strategist Jared Holz joins Morning Brief to give insight into the healthcare sector and what investors should keep in mind moving forward. "I think for me, Novo and Lilly are still going to be the top two. You know, as long as they are dominating in this kind of section of the market, it's really tough to not ride these a little bit longer, as far as other players in the GLP one market that might emerge that are of interest or intrigue to investors," Holz says. For more expert insight and the latest market action, click here to watch this full episode of Morning Brief. This post was written by Nicholas Jacobino Follow Yahoo Finance's latest coverage on Eli Lilly and Novo Nordisk, weight-loss drugs, and the pharmaceutical industry as a whole: How Lilly is joining Novo in the crusade to circumvent Medicare's block on weight loss drugs Eli Lilly seeks to expand Zepbound use to treat sleep apnea Eli Lilly and Novo Nordisk are a 'duopoly' in GLP-1 market Why the GLP-1 impact on other industries 'will take years' Eli Lilly unveils new manufacturing plant for GLP-1 pens Novo Nordisk to invest $4.1B in NC facility for GLP-1 drugs Eli Lilly's new Alzheimer's treatment could 'lift' drug market Novo Nordisk stock rises on Wegovy approval in China
ZacksEli Lilly (LLY) Stock Drops Despite Market Gains: Important Facts to Note
In the most recent trading session, Eli Lilly (LLY) closed at $901.26, indicating a -0.37% shift from the previous trading day.
